Archive for November, 2012
NovaBay Swings for the Fences with NVC-422 Trial In Viral Conjunctivitis
Investment Thesis Although NovaBay is a small company as judged by its $43 million market capitalization, it is complex to analyze. It is developing one molecule, NVC-422, for three separate indications, impetigo, viral conjunctivitis and urinary encrustation and blockage. While the molecule is the same, the disease states are quite different as is the formulation: […]
My Buy Rating on Cadence Pharmaceticals is Bolstered by Ofirmev Patent Settlement with Perrigo
Investment Conclusion Today’s announcement that Cadence (CADX) has entered into a settlement with Perrigo (PRGO) on patent litigation regarding Ofirmev is a positive. Uncertainty over the patent situation of Ofirmev has been a dark cloud over Cadence’s stock. This settlement is encouraging, but Cadence still has another generic challenger to deal with in Exela Pharma […]
Initiating Coverage of Neuralstem with a Buy (CUR, $0.92)
Product Development Overview This report provides an introduction to stem cells and the cells that comprise the central nervous system. Basic knowledge of both is needed to understand the investment thesis for Neuralstem. Its technology platform is based on first isolating neural stem cells from fetal tissue and then expanding them in cell cultures to […]
Focusing on the Impetigo Indication for NVC-422 (NBY, $1.29)
Investment Thesis Although NovaBay(NBY) is a small company as judged by its $37 million market capitalization, it is complex to analyze. It is developing one molecule, NVC-422, for three separate indications, impetigo, viral conjunctivitis and urinary catheter encrustation and blockage. While the molecule is the same, the disease states are quite different as is the […]